ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like Biogen Taps Biotech Vet as New CFO November 20, 2017 Bioanalytical Systems, Inc. To Release First Quarter Fiscal 2017 Results On Tuesday, February 14, 2017 February 12, 2017 Never Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by $5 Billion March 27, 2017
Bioanalytical Systems, Inc. To Release First Quarter Fiscal 2017 Results On Tuesday, February 14, 2017 February 12, 2017
Never Say Never: Why Taking Out Bristol-Myers Squibb Could Boost Pfizer's Value by $5 Billion March 27, 2017
